PolyPid Advances Toward D-PLEX100 Launch and Extends Financial Runway into 2028
During its third quarter 2026 earnings call, biopharmaceutical company PolyPid (PYPD) reported significant progress toward the commercial launch of D-PLEX100. The company is approaching a PDUFA target date of November 28, 2026, for the drug intended to prevent surgical site infections. Commercial partner Azurity Pharmaceuticals has already established distribution channels reaching over 1,700 U.S. hospitals in preparation for an early 2027 rollout. Strategically, PolyPid has regained exclusive rights to its European market following the termination of its agreement with ADVANZ PHARMA. This move allows the company full control over its European strategy while it seeks new regional partners. Financially, a $15 million milestone payment from Azurity in October, combined with existing cash reserves, provides sufficient funding for operations and clinical trials through 2028 without immediate need for capital dilution.
Tickers: $PYPD
Topics: biopharmaceutical commercial launch FDA PDUFA date milestone payments regulatory approval